According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173991724The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.Use of autoinjectors in the treatment of rheumatoid arthritis drives the global autoinjectors marketRheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that affects connective tissues. It causes joints to swell and can result in pain, stiffness, and progressive loss of function. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US annually are affected by some form of arthritis, RA, gout, lupus, or fibromyalgia.Global Autoinjectors Market Segmentation:+ On the basis of type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to account for the largest market share in 2017. This can primarily be attributed to their ease of use and the presence of a built-in glass syringe which makes it more convenient for patients with reduced dexterity or visual impairments.+ On the basis of therapy, the market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). The rheumatoid arthritis segment accounted for the largest share of the market in 2017. The large share of this segment is mainly attributed to the high prevalence of rheumatoid arthritis across the globe.+ On the basis of end users, the market is segmented into home care settings and hospitals & clinics. The home care settings segment commanded the largest share of the market in 2017. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724What Drives the Market?1. Growing prevalence of targeted therapies2. Rising incidence of anaphylaxis3. Increasing number of regulatory approvals4. Availability of generic versions of autoinjectorsGeographical Growth Analysis:In 2018, North America is expected to account for the largest share of the autoinjectors market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, rising prevalence of anaphylaxis in the US, and rising prevalence of autoimmune and chronic diseases in the US and Canada are contributing to the large share of North America.Key Players and Strategies Adopted by Them:The key players in the global autoinjectors market are Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). The other prominent players in the market are J&J (US), Novartis (Switzerland), Bayer (Germany), Merck (Germany), Biogen (US), Ypsomed (Switzerland), SHL Group (Taiwan) Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).
Market growth can be attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, rising geriatric population and rising labor cost. On the other hand, reluctance among the healthcare organizations to adopt pharmacy automation systems is expected to restrain the overall market growth to a certain extent during the forecast period. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.According to the new market research report "Pharmacy Automation Market by Product (Medication Dispensing System (Robot, Carousel), Packaging & Labeling System (Unit Dose, Multi Dose), Tabletop Counter, Storage System), End User (Inpatient, Outpatient, Retail Pharmacy) - Global Forecast to 2022", published by MarketsandMarkets™, The overall pharmacy automation market is estimated to grow at a CAGR of 8.2% from 2017 to 2022 to reach USD 5.38 Billion by 2022.Download PDF Brochure :https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71522890
Market segmented into :1. Pharmacy automation systems refer to a variety of systems and software designed to increase the productivity of pharmacies and precision of the medication compounding process by reducing human intervention. Automated systems mechanize various procedures in pharmacies, including the storage, packaging, dispensing, pickup, delivery, and distribution of drugs.2. The market has been segmented on the basis of product, into automated medication dispensing systems, automated packaging and labelling systems, automated table top counters, automated medication compounding systems, automated storage and retrieval systems, and other pharmacy automation systems. The market for automated packaging and labelling systems is expected to grow at the highest CAGR between 2017 and 2022.3. The pharmacy automation market in APAC is expected to grow at the highest CAGR during the forecast period. APAC is the fastest-growing market for pharmacy automation systems. Increasing healthcare spending and government initiatives to develop HCIT infrastructure has increased the growth of market in this region. On the other hand, with the rapid rise in the number of patients, demand for quality care, and effective upgradation of the Healthcare IT infrastructure is expected to have a positive impact on the demand for pharmacy automation systems market in APAC region.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=71522890Geographical Growth Analysis:The high costs of implementation of pharmacy automation systems and stringent regulations that delay product launches can inhibit growth of this market. Despite their benefits, a number of healthcare professionals and providers are reluctant to adopt or accept any IT-based approach for pharmacy management. Many pharmacists do not feel the need for assistance and are therefore, reluctant to adopt pharmacy automation systems as part of their dispensing regimen. Moreover, for small hospitals and pharmacies, the cost of implementation is too high.Some of The Major Players In Anatomic Pathology Market:Becton, Dickinson, and Company (U.S.), Omnicell, Inc. (U.S.), Cerner Corporation (U.S.), Capsa Healthcare (U.S.), Parata Systems LLC (U.S), Baxter International, Inc. (U.S.), ScriptPro LLC (U.S.), KUKA AG (Germany), TCGRx Pharmacy Workflow Solutions (U.S.), RxSafe, LLC (U.S.), ARxIUM Inc. (U.S.) and Talyst systems LLC. (U.S.).
According to the new market research report "Glycomics / Glycobiology Market by Product (Enzymes (Glycosyltransferase, Glycosidase), Instruments (HPLS, Mass Spectrometry, MALDITOF), Kits & Reagents (Glycoproteins)), Application (Diagnostic, Drug Discovery, Oncology), End User - Global Forecast to 2021", published by MarketsandMarkets™, The global glycobiology market is expected to reach USD 1,211.4 million by 2021 from USD 649.5 million in 2016, at a CAGR of 13.3%.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132685525Glycobiology is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes. This study is used in diagnostics, drug discovery research, immunology, oncology, and various other applications. Glycobiology products are widely used for analysis of cell surface markers, which can act as diagnostic or therapeutic targets. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.The following are the major objectives of the study :1. To define, describe, and forecast the global glycobiology market on the basis of product, application, end user, and region2. To provide detailed information regarding the major factors influencing the growth of the glycobiology market (drivers, restraints, opportunities, and industry-specific challenges)3. To strategically analyze the micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall Glycobiology market4. To analyze the opportunities in the market for stakeholders and to provide details of the competitive landscape for market leaders5. To forecast the Glycobiology market size of the market segments with respect to four main regional segments, namely, North America, Europe, Asia, and the Rest of the World6. To strategically profile the key players and comprehensively analyze their market shares and core competencies27. To track and analyze the competitive developments such as new product launches, agreements, collaborations, acquisitions, expansion and agreements in the glycomics marketGet Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132685525Key Players and Strategies Adopted by Them:The key players in the glycobiology market include Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.).Oncology :Glycomics plays a crucial role in analyzing the molecular mechanism of various types of cancers. Glycomics also plays an important role in identifying new biomarkers for cancers. Biomarkers are used as key diagnostic targets for various types of cancers. They can also be used for devising novel and personalized therapies for cancer patients. Owing to its ability to differentiate between protein sub-types based on the molecular structure of their glycan patterns, glycomics has emerged as an important research tool for the discovery and validation of protein-based cancer biomarkers.
The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 Million by 2021 from USD 202.8 Million in 2016, at a CAGR of around 10.5% during the forecast period.
The key trends for increase in market, by public health organization are the growing expenditure on drugs and medical devices by public health organizations, steps by the government to build up strong analytical testing abilities, increasing number of drug approvals and clinical trials, and rising demand for specialized analytical testing services. However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support
To know about the assumptions considered for the study, download the pdf brochure, visit:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65590498
According to the new market research report "Analytical Laboratory Services Market by Public Health Organization, - by types of services (Stability, Raw Material, Physical Characterization, Method Validation, Microbial Testing, Environmental Monitoring, Bioanalytical Testing) - Forecast to 2021", published by MarketsandMarkets™, The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 Million by 2021 from USD 202.8 Million in 2016, at a CAGR of around 10.5% during the forecast period.
Don’t miss out on business opportunities in Analytical Laboratory Services Market, visit: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65590498
The overall market, by public health organization is positively impacted by factors such as the growing expenditure on drugs and medical devices by public health organizations, government initiatives to strengthen analytical testing capabilities, increasing number of drug approvals & clinical trials, and rising demand for specialized analytical testing services.
However, complex and innovative pharmaceutical products requiring a distinctive analytical testing approach is the major challenge hampering the growth of government support on analytical laboratory services.
Browse and in-depth TOC on "Analytical Laboratory Services Market"
37 - Tables
7 - Figures
68 - Pages
On the basis of type of service, the spend assessment is segmented into eight segments, namely, bioanalytical testing, batch release testing, stability testing, raw material testing, physical characterization, method validation, microbial testing, and environmental monitoring.
Read More Report @ https://www.marketsandmarkets.com/PressReleases/analytical-laboratory-services.asp
In this report, the market is segmented by tool, technology, application, and region. On the basis tool, the synthetic biology market is segmented into oligonucleotides, enzymes, cloning technology kits, chassis organisms, and
xeno-nucleic acids. The chassis organisms segment is expected to grow at the highest rate during the forecast period. The increasing demand for green alternatives (biomass is converted to chemicals using engineered bacteria, yeasts, and other microorganisms) to fossil fuels is a key driver for this segment.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889
Synthetic biology has an array of applications in the fields of medicine, agriculture, nanotechnology, and industrial biotechnology. This has attracted interests of researchers from across the globe and has led to a rise in funding from public and private organizations, which, in turn, help in the growth of the market.Synthetic Biology Market segmented into :+ The global synthetic biology market is segmented on the basis of tool, technology, application, and region. Based on tools, the market is segmented into oligonucleotides, enzymes, cloning technology kits, chassis organisms, and xeno-nucleic acids.+ By technology, the market is segmented into gene synthesis, genome engineering, cloning and sequencing, next-generation sequencing, site-directed mutagenesis, measurement and modeling, microfluidics, and nanotechnology.+ The market is segmented into medical (pharmaceutical, drug discovery & therapeutics, and artificial tissue and tissue regeneration), industrial (biofuel & renewable energy, industrial enzymes, and biomaterials & green chemicals), food & agriculture, and environmental (bioremediation and biosensing) on the basis of application.Get Sample Copy of This Report@https://www.marketsandmarkets.com/requestsampleNew.asp?id=889What Drives the Market?1. Wide Range of Applications of Synthetic Biology2. Rising R&D Funding and Initiatives in Synthetic Biology3. Increasing Demand for Synthetic Genes and Synthetic Cells4. Increasing Investments in Synthetic Biology CompaniesGeographical Growth Analysis:The market in Europe is expected to register the highest growth rate from 2017 to 2022. The rising international alliances between the European countries and other countries and heavy funding from the government to foster the synthetic biology research in Europe are major factors driving the growth of market in this region. Additionally, factors such as increasing investments for the adoption of novel synthetic biology technologies, rising R&D funding and collaborations are driving the growth of the market in this region.Key Players and Strategies Adopted by Them:Key players in the global Synthetic Biology Market include Thermo Fisher (US), Novozymes (Denmark), Merck KGaA (Germany), Intrexon (US), and Agilent Technologies (US), Amyris (US), GenScript (US), Ginkgo Bioworks (US), Integrated DNA Technologies (US), New England Biolabs (US), Synthetic Genomics (US), and Twist Bioscience (US). These players are increasingly collaborating, and partnering with companies to offer their synthetic oligonucleotides and to develop synthetic organisms.Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=889
Synthetic biology has an array of applications in the fields of medicine, agriculture, nanotechnology, and industrial biotechnology. This has attracted interests of researchers from across the globe and has led to a rise in funding from public and private organizations, which, in turn, help in the growth of the market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889
Global Synthetic Biology Market Segmentation:In this report, the market is segmented by tool, technology, application, and region. On the basis tool, the synthetic biology market is segmented into oligonucleotides, enzymes, cloning technology kits, chassis organisms, and xeno-nucleic acids. The chassis organisms segment is expected to grow at the highest rate during the forecast period. The increasing demand for green alternatives (biomass is converted to chemicals using engineered bacteria, yeasts, and other microorganisms) to fossil fuels is a key driver for this segment.By technology, the market is segmented into gene synthesis, genome engineering, cloning and sequencing, next-generation sequencing, site-directed mutagenesis, measurement and modeling, microfluidics, and nanotechnology. In 2017, the gene synthesis segment is expected to account for the largest share of the market in technology.The market is segmented into medical (pharmaceutical, drug discovery & therapeutics, and artificial tissue and tissue regeneration), industrial (biofuel & renewable energy, industrial enzymes, and biomaterials & green chemicals), food & agriculture, and environmental (bioremediation and biosensing) on the basis of application.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=889What Drives the Market?1. Wide Range of Applications of Synthetic Biology2. Rising R&D Funding and Initiatives in Synthetic Biology3. Increasing Demand for Synthetic Genes and Synthetic Cells4. Increasing Investments in Synthetic Biology CompaniesGeographical Growth Analysis:The market in Europe is expected to register the highest growth rate from 2017 to 2022. The rising international alliances between the European countries and other countries and heavy funding from the government to foster the synthetic biology research in Europe are major factors driving the growth of market in this region. Additionally, factors such as increasing investments for the adoption of novel synthetic biology technologies, rising R&D funding and collaborations are driving the growth of the market in this region.Key Players and Strategies Adopted by Them:Key players in the global Synthetic Biology Market include Thermo Fisher (US), Novozymes (Denmark), Merck KGaA (Germany), Intrexon (US), and Agilent Technologies (US), Amyris (US), GenScript (US), Ginkgo Bioworks (US), Integrated DNA Technologies (US), New England Biolabs (US), Synthetic Genomics (US), and Twist Bioscience (US). These players are increasingly collaborating, and partnering with companies to offer their synthetic oligonucleotides and to develop synthetic organisms.Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=889
The cell therapy technologies market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4%. Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=213334978Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market.Global Cell Therapy Technologies Market Segmentation:By product, the cell therapy technologies market is segmented into consumables, equipment, and systems & software. The consumables segment is expected to account for the largest share of the market in 2018. Factors such as increasing investments by companies to develop advanced products as well as government initiatives for enhancing cell-based research are contributing to the growth of the cell therapy consumables market.Based on process, the cell therapy technologies market is segmented into cell processing; cell preservation, distribution, and handling; and process monitoring and quality control. The cell processing segment is expected to account for the largest market share in 2018 and is projected to witness the highest CAGR during the forecasted period.Based on cell type, the market is segmented into human cells and animal cells. In 2018, the human cells segment is expected to account for the largest share of the cell therapy technologies market. The rising adoption of human cells over animal cells for cell therapeutics research, technological advancements, and the rising incidence of diseases such as cancer and cardiac abnormalities are the key factors driving the growth of this segment.Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=213334978What Drives the Market?1. Rising Government Investments in Cell-Based Research2. Large Number of Oncology-Oriented Cell-Based Therapy Clinical Trials3. Affordability and Sustainability of Advanced Cell Therapy InstrumentsGeographical Growth Analysis:The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the market in 2018 owing to the high burden of chronic diseases and increasing R&D activities in the pharmaceutical and biotechnology industries. The Asia Pacific region is expected to register the highest CAGR during the forecast period. The increasing demand for cell therapy instruments and products from China, India, and Japan primarily due to the increasing research funding for vaccine development and changing disease profiles is supporting the growth of the market in the Asia Pacific.Key Players and Strategies Adopted by Them:Key players in this cell therapy technologies market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=213334978
